Deoxynucleoside Analogs In Cancer Therapy

  • Godefridus J. Peters

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Marçal Pastor-Anglada, F. Javier Casado
    Pages 1-28
  3. Sally Anne Hunsucker, Beverly S. Mitchell, Jozef Spychala
    Pages 81-108
  4. Piet Borst, Peter Wielinga
    Pages 109-117
  5. Isabelle Hubeek, Gert-Jan L. Kaspers, Gert J. Ossenkoppele, Godefridus J. Peters
    Pages 119-152
  6. Varsha Gandhi, William Plunkett
    Pages 153-171
  7. Giuseppe Gumina, Youhoon Chong, Chung K. Chu
    Pages 173-198
  8. Henriette Gourdeau, Jacques Jolivet
    Pages 199-214
  9. Sophie Curbo, Anna Karlsson
    Pages 215-224
  10. Andries M. Bergman, Godefridus J. Peters
    Pages 225-251
  11. Judith R. Kroep, Godefridus J. Peters, Robert A. Nagourney
    Pages 253-288
  12. Donna S. Shewach, Theodore S. Lawrence
    Pages 289-329
  13. Chris Meier, Jan Balzarini, Astrid Meerbach
    Pages 353-401
  14. Zoran Gojkovic, Anna Karlsson
    Pages 403-439
  15. Wieteke G. E. Direcks, Adriaan A. Lammertsma, Carla F. M. Molthoff
    Pages 441-462
  16. Back Matter
    Pages 463-476

About this book


Emerging as an important new volume in the renowned Cancer Drug Discovery and Development™ series, Deoxynucleoside Analogs in Cancer Therapy expertly summarizes the current status of development and application of deoxynucleoside analogs. Authoritative up-to-date reviews are presented by scientists well known in their specific areas and all contributions include valuable sound advice on structure and topics.
Organized into several sections, the first part covers general aspects of drug uptake and metabolism and explains how novel technology has enabled a rapid expansion of this field. The second part is concerned with a number of specific drugs including cytarabine, gemcitabine, troxacitabine, clofarabine and Ara-G. The final section covers pharmacokinetics, prodrugs, and specific applications such as radiosensitization, gene therapy, and the use of deoxynucleoside analogs as tracers.
Throughout Deoxynucleoside Analogs in Cancer Therapy, the focus is on novel aspects of deoxynucleoside analogs in the clinical context, as well as on unexpected targets of these compounds, such as their specific activity against cell cycle-dependent kinases or oncogenes. The wealth of information presented here can be used to design rational combinations aimed at inhibiting various cellular signaling pathways, or combining inhibition of various targets. Deoxynucleoside Analogs in Cancer Therapy has been designed specifically to facilitate such an interaction between various fields.


HIV cancer cancer therapy cell chemotherapy drug drug discovery gene therapy kinetics leukemia metabolism oncogenes pancreatic cancer pharmacokinetics research

Editors and affiliations

  • Godefridus J. Peters
    • 1
  1. 1.VU University Medical Center AmsterdamThe Netherlands

Bibliographic information